• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Analytic Response Curves of Clinical Breast Cancer IHC Tests.临床乳腺癌免疫组化检测的分析反应曲线
J Histochem Cytochem. 2017 May;65(5):273-283. doi: 10.1369/0022155417694869. Epub 2017 Jan 1.
2
The Importance of Epitope Density in Selecting a Sensitive Positive IHC Control.表位密度在选择敏感的免疫组化阳性对照中的重要性。
J Histochem Cytochem. 2017 Aug;65(8):463-477. doi: 10.1369/0022155417714208. Epub 2017 Jun 30.
3
Quantitative Assessment of Immunohistochemistry Laboratory Performance by Measuring Analytic Response Curves and Limits of Detection.通过测量分析反应曲线和检测限来定量评估免疫组织化学实验室性能。
Arch Pathol Lab Med. 2018 Jul;142(7):851-862. doi: 10.5858/arpa.2017-0330-OA. Epub 2018 Mar 29.
4
Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer.年龄与可手术浸润性乳腺癌中类固醇和HER-2受体的表达相互作用。
Breast Cancer Res Treat. 2008 Jul;110(1):153-9. doi: 10.1007/s10549-007-9687-4. Epub 2007 Aug 9.
5
Standardizing Immunohistochemistry: A New Reference Control for Detecting Staining Problems.标准化免疫组织化学:一种检测染色问题的新参考对照
J Histochem Cytochem. 2015 Sep;63(9):681-90. doi: 10.1369/0022155415588109. Epub 2015 May 4.
6
Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations.乳腺癌中雌激素受体、孕激素受体及人表皮生长因子受体2表达的免疫组化检测:细胞块、针芯活检及组织块标本的比较
Cancer. 2009 Aug 25;117(4):279-88. doi: 10.1002/cncy.20034.
7
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.雌激素受体阳性、孕激素受体阴性乳腺癌:与生长因子受体表达及他莫昔芬耐药性的关联
J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61. doi: 10.1093/jnci/dji249.
8
Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer.在评估浸润性乳腺癌的雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER-2)时,手术标本可用芯针活检样本替代。
Acta Oncol. 2008;47(1):38-46. doi: 10.1080/02841860701441822.
9
Prognostic implications of HER-2 status in steroid receptor-positive, lymph node-negative breast carcinoma.HER-2状态在激素受体阳性、淋巴结阴性乳腺癌中的预后意义。
Am J Clin Pathol. 2007 May;127(5):780-6. doi: 10.1309/FWHEQX6HB9190LVY.
10
The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.乳腺癌患者从原发性病灶到转移病灶的激素受体及人表皮生长因子受体2(Her-2)状态的变化及其临床意义
Tumour Biol. 2016 Jun;37(6):7675-84. doi: 10.1007/s13277-015-4649-7. Epub 2015 Dec 21.

引用本文的文献

1
Comparing the Sensitivity of HER2 Epitope Detection of HercepTest mAb pharmDx (Dako Omnis, GE001) and Ventana PATHWAY Anti-HER-2/neu (4B5) Using IHC Calibrators.比较 HercepTest mAb pharmDx(Dako Omnis,GE001)和 Ventana PATHWAY Anti-HER-2/neu(4B5)两种免疫组化试剂检测 HER2 表位的敏感性,使用 IHC 校准品。
Appl Immunohistochem Mol Morphol. 2024;32(10):469-475. doi: 10.1097/PAI.0000000000001230. Epub 2024 Oct 24.
2
A Consortium for Analytic Standardization in Immunohistochemistry.免疫组织化学分析标准化联合会。
Arch Pathol Lab Med. 2022 May 1;147(5):584-590. doi: 10.5858/arpa.2022-0031-RA.
3
Tissue Multiplex Analyte Detection in Anatomic Pathology - Pathways to Clinical Implementation.解剖病理学中的组织多重分析物检测——临床应用途径
Front Mol Biosci. 2021 Jul 27;8:672531. doi: 10.3389/fmolb.2021.672531. eCollection 2021.
4
Development and Validation of Measurement Traceability for In Situ Immunoassays.现场免疫分析的测量可追溯性的开发和验证。
Clin Chem. 2021 Apr 29;67(5):763-771. doi: 10.1093/clinchem/hvab008.
5
Synthetic Antigen Gels as Practical Controls for Standardized and Quantitative Immunohistochemistry.合成抗原凝胶作为标准化和定量免疫组织化学的实用对照。
J Histochem Cytochem. 2019 May;67(5):309-334. doi: 10.1369/0022155419832002. Epub 2019 Mar 18.
6
A Root Cause Analysis Into the High Error Rate in Clinical Immunohistochemistry.临床免疫组织化学高错误率的根本原因分析
Appl Immunohistochem Mol Morphol. 2019 May/Jun;27(5):329-338. doi: 10.1097/PAI.0000000000000750.
7
Selecting an Optimal Positive IHC Control for Verifying Antigen Retrieval.选择最佳的阳性免疫组化(IHC)对照以验证抗原修复。
J Histochem Cytochem. 2019 Apr;67(4):275-289. doi: 10.1369/0022155418824092. Epub 2019 Jan 10.
8
The Importance of Epitope Density in Selecting a Sensitive Positive IHC Control.表位密度在选择敏感的免疫组化阳性对照中的重要性。
J Histochem Cytochem. 2017 Aug;65(8):463-477. doi: 10.1369/0022155417714208. Epub 2017 Jun 30.

本文引用的文献

1
Certified DNA Reference Materials to Compare HER2 Gene Amplification Measurements Using Next-Generation Sequencing Methods.用于通过下一代测序方法比较HER2基因扩增测量值的认证DNA参考材料。
J Mol Diagn. 2016 Sep;18(5):753-761. doi: 10.1016/j.jmoldx.2016.05.008. Epub 2016 Jul 25.
2
Development of NIST standard reference material 2373: Genomic DNA standards for HER2 measurements.美国国家标准与技术研究院标准参考物质2373的研制:用于HER2测量的基因组DNA标准品
Biomol Detect Quantif. 2016 Mar 9;8:1-8. doi: 10.1016/j.bdq.2016.02.001. eCollection 2016 Jun.
3
Standardizing Immunohistochemistry: A New Reference Control for Detecting Staining Problems.标准化免疫组织化学:一种检测染色问题的新参考对照
J Histochem Cytochem. 2015 Sep;63(9):681-90. doi: 10.1369/0022155415588109. Epub 2015 May 4.
4
Quantification of HER family receptors in breast cancer.乳腺癌中HER家族受体的定量分析。
Breast Cancer Res. 2015 Apr 9;17:53. doi: 10.1186/s13058-015-0561-8.
5
Comparison of anti-estrogen receptor antibodies SP1, 6F11, and 1D5 in breast cancer: lower 1D5 sensitivity but questionable clinical implications.比较乳腺癌中的抗雌激素受体抗体 SP1、6F11 和 1D5:1D5 敏感性较低,但临床意义值得怀疑。
Am J Clin Pathol. 2012 Nov;138(5):697-702. doi: 10.1309/AJCPLX0QJROV2IJG.
6
Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach.采用组织微阵列方法测定乳腺癌 HER2 检测的敏感性和特异性。
Breast Cancer Res. 2012 Jun 13;14(3):R93. doi: 10.1186/bcr3208.
7
Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells.乳腺癌中雌激素受体测量的标准化表明假阴性结果是阈值强度的函数,而不是阳性细胞的百分比。
J Clin Oncol. 2011 Aug 1;29(22):2978-84. doi: 10.1200/JCO.2010.32.9706. Epub 2011 Jun 27.
8
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.用于测量细胞系和乳腺癌中 HER1-HER2 异二聚体化和磷酸化的定量检测方法:用于诊断和靶向药物作用机制的应用。
Breast Cancer Res. 2011 Apr 15;13(2):R44. doi: 10.1186/bcr2866.
9
The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas.兔单克隆抗体在人乳腺癌雌激素受体、孕激素受体和 HER2 免疫组织化学评估中的可靠性。
Am J Clin Pathol. 2010 Oct;134(4):621-32. doi: 10.1309/AJCPOG3O3KTPZQNK.
10
Cell lines as candidate reference materials for quality control of ERBB2 amplification and expression assays in breast cancer.细胞系作为乳腺癌中ERBB2扩增和表达检测质量控制的候选参考物质。
Clin Chem. 2009 Jul;55(7):1307-15. doi: 10.1373/clinchem.2008.120576. Epub 2009 May 14.

临床乳腺癌免疫组化检测的分析反应曲线

Analytic Response Curves of Clinical Breast Cancer IHC Tests.

作者信息

Vani Kodela, Sompuram Seshi R, Schaedle Anika K, Balasubramanian Anuradha, Bogen Steven A

机构信息

Medical Discovery Partners LLC, Boston, Massachusetts (KV, SRS, AKS, AB, SAB), and Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, Massachusetts (SAB).

出版信息

J Histochem Cytochem. 2017 May;65(5):273-283. doi: 10.1369/0022155417694869. Epub 2017 Jan 1.

DOI:10.1369/0022155417694869
PMID:28438091
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5407532/
Abstract

An important limitation in the field of immunohistochemistry (IHC) is the inability to correlate stain intensity with specific analyte concentrations. Clinical immunohistochemical tests are not described in terms of analytic response curves, namely, the analyte concentrations in a tissue sample at which an immunohistochemical stain (1) is first visible, (2) increases in proportion to the analyte concentration, and (3) ultimately approaches a maximum color intensity. Using a new immunostaining tool ( IHControls), we measured the analytic response curves of the major clinical immunohistochemical tests for human epidermal growth factor receptor type II (HER-2), estrogen receptor (ER), and progesterone receptor (PR). The IHControls comprise the analytes HER-2, ER, and PR at approximately log concentration intervals across the range of biological expression, from 100 to 1,000,000 molecules per test microbead. We stained IHControls of various concentrations using instruments, reagents, and protocols from three major IHC vendors. Stain intensity at each analyte concentration was measured, thereby generating an analytic response curve. We learned that for HER-2 and PR, there is significant variability in test results between clinical kits for samples with analyte concentrations of approximately 10 molecules/microbead. We propose that the characterization of immunostains is an important step toward standardization.

摘要

免疫组织化学(IHC)领域的一个重要局限是无法将染色强度与特定分析物浓度相关联。临床免疫组织化学检测并未按照分析反应曲线进行描述,也就是说,未描述组织样本中分析物浓度与免疫组织化学染色之间的关系,即(1)染色首次可见时的分析物浓度,(2)染色强度随分析物浓度成比例增加,以及(3)最终接近最大颜色强度时的分析物浓度。我们使用一种新的免疫染色工具(IHControls),测量了针对人表皮生长因子受体2型(HER-2)、雌激素受体(ER)和孕激素受体(PR)的主要临床免疫组织化学检测的分析反应曲线。IHControls包含HER-2、ER和PR分析物,在每个测试微珠上,其浓度范围跨越生物表达范围,以大约对数浓度间隔分布,从每微珠100到1,000,000个分子。我们使用来自三家主要免疫组织化学供应商的仪器、试剂和方案,对不同浓度的IHControls进行染色。测量每个分析物浓度下的染色强度,从而生成分析反应曲线。我们发现,对于HER-2和PR,分析物浓度约为10个分子/微珠的样本,临床试剂盒之间的检测结果存在显著差异。我们认为免疫染色特性的表征是迈向标准化的重要一步。